Sign in
4

Changes in Ownership

Entrada Therapeutics, Inc. Filed Acc 0001104659-22-092658

Chief Financial Officer sold 600 shares at an average $13.02 ($7,814)

  • Chief Financial Officer acquired 300 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

WENTWORTH KORY JAMES · Chief Financial Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2022-08-16 Exercise or conversion : show line 1 in the form +100 $2.10 $210 20,641 D
2022-08-16 Sale : show line 2 in the form −200 $13.00 $2,600 20,441 D
2022-08-17 Exercise or conversion : show line 3 in the form +100 $2.10 $210 20,541 D
2022-08-17 Sale : show line 4 in the form −200 $13.07 $2,614 20,341 D
2022-08-18 Exercise or conversion : show line 5 in the form +100 $2.10 $210 20,441 D
2022-08-18 Sale : show line 6 in the form −200 $13.00 $2,600 20,221 D
Open-market sales · 600 sh · avg $13.02 · $7,814

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2022-08-16 Exercise or conversion : show line 7 in the form Stock Option (Right to Buy) −100 116,096 D
2022-08-17 Exercise or conversion : show line 8 in the form Stock Option (Right to Buy) −100 115,996 D
2022-08-18 Exercise or conversion : show line 9 in the form Stock Option (Right to Buy) −100 115,896 D
Loading xslF345X03/tm2224086-1_4seq1.xml…